Alan Collis will be joining as the leader of the SynVent team. SynVent is Syngene's platform for integrated discovery and early development, delivering upon strategies built in collaboration with and on behalf of clients to advance novel molecules into clinical trials. He will be responsible for the formulation and implementation of Syngene's overall Integrated Drug Discovery (IDD) scientific strategy and will oversee the end-to-end execution of client programs. He reports to Kenneth Barr, Sr. Vice President, Discovery Services.
Commenting on the appointments, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Ltd., said, "As we continue our rapid growth in the global CRO/CDMO marketplace, these hires align with Syngene's focus on providing end-to-end solutions for discovery, development, and manufacturing across a range of therapeutic areas and modalities. We look forward to having Alex and Alan on board, which will help strengthen our position as a partner in innovation for our clients and to steer Syngene towards new growth milestones."
Alex Del Priore said, "I am delighted to take on my new role at Syngene and contribute towards pushing the boundaries of science in manufacturing and advanced therapies in biologics. As part of an integrated scientific solutions provider for multiple industries, I look forward to the exciting journey."
Alex Del Priore has an impeccable track record of over two decades in the development, commercialization, and life-cycle management of products in various lifescience industries. He has also served as general manager with global P&L responsibility. In addition, he has been instrumental in M&A, strategy development, & new product introduction.
Alan Collis said, "As a 'hand on' cross-functional scientist, I am thrilled to have this opportunity to join and help grow Syngene. I aim to swiftly progress the great scientific insights of our partners into clinical evaluation. The path requires a thoroughly connected and integrated strategy sitting squarely across our multiple proven capabilities in research, development, and manufacturing."
Alan Collis is a drug discovery and development scientist specializing in discovery, preclinical, and early clinical project leadership. Alan has served the European and US markets in various leadership roles, with responsibilities including medicinal chemistry, DMPK, safety assessment, CMC, and phase I studies. He has led 33 novel small molecules into preclinical evaluation by partnering with a diverse set of teams (internal and external) that initiated multiple clinical studies of new science.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.